Year: 2010
Type: review
Abstract: Colorectal cancer (CRC) is the third most common epithelial malignancy in the world. Since CRC develops slowly from removable precancerous lesions, detection of the lesion at an early stage by regular health examinations can reduce the incidence and mortality of this malignancy. Colonoscopy significantly improves the detection rate of CRC, but the examination is expensive and inconvenient. Therefore, we need novel biomarkers that are non-invasive to enable us to detect CRC quite early. A number of validation studies have been conducted to evaluate genetic, epigenetic or protein markers for identification in the stool and/or serum. Currently, the fecal occult blood test is the most widely used method of screening for CRC. However, advances in genomics and proteomics will lead to the discovery of novel non-invasive biomarkers.
DOI: 10.3390/ijms11093209
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,499
Awards: G1082161905, 炎症性大腸発がんモデルマウスを用いた共役リノレン酸の発がん阻止効果に関する研究, G1510232949, G2406506678, G3865019376, G4253402111, Methylation of GST-P-positive tongue preneoplastic lesions, G5499588114, Strategy for the chemoprevention of hepatocellular carcinoma by targeting phosphorylated RXRa, G7110576571, G7715091689
OpenAlex ID: W2010754117